marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2023
added 10-19-2024
RedHill Biopharma Ltd. Balance Sheet 2011-2024 | RDHL
Annual Balance Sheet RedHill Biopharma Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | 53.8 M | -25.2 M | - | - | -53.8 M | -5.99 M | -5.89 M | -11.9 M | -16.8 M | -14.1 M | ||
Long Term Debt |
- | - | - | 81.4 M | 2.98 M | - | - | - | - | - | - | - | - |
Long Term Debt Current |
718 K | 1.03 M | 1.62 M | 1.71 M | 834 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 3.48 M | 844 K | 448 K | 6.16 M | 1.24 M | 2.12 M | - | - | 886 K |
Total Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
21 M | 207 M | 172 M | 166 M | 14.1 M | 11.2 M | 12.3 M | 11.5 M | 6.75 M | 3.84 M | 2.42 M | 1.08 M | 1.4 M |
Deferred Revenue |
- | - | - | 19.5 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | -280 M | -208 M | -169 M | -133 M | -88.6 M | -60.9 M | -42.2 M | -33.3 M | -23.9 M | -15.2 M |
Total Assets |
23 M | 159 M | 181 M | 180 M | 74.1 M | 62.4 M | 57.3 M | 74.2 M | 66.8 M | 28.9 M | 14.3 M | 20.1 M | 20.2 M |
Cash and Cash Equivalents |
5.57 M | 20 M | 29.5 M | 29.3 M | 29 M | 29 M | 16.5 M | 53.8 M | 21.5 M | - | - | - | - |
Book Value |
2.07 M | -48.4 M | 8.88 M | 13.9 M | 60 M | 51.2 M | 45.1 M | 62.7 M | 60.1 M | 25 M | 11.9 M | 19 M | 18.8 M |
Total Shareholders Equity |
- | - | - | 13.9 M | 60 M | 51.2 M | 45.1 M | 62.7 M | 60.1 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet RedHill Biopharma Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | 2.57 M | - | 2.98 M | - | 3.81 M | - | 4.04 M | - | 2.98 M | - | 3.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 90.8 M | - | 94.9 M | - | 93.1 M | - | 95.9 M | - | 3.48 M | - | 3.74 M | - | 844 K | - | - | - | 448 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 172 M | - | 174 M | - | 166 M | - | 132 M | - | 14.1 M | - | 17.8 M | - | 11.2 M | - | 11.9 M | - | 12.3 M | - | - | - | 11.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | - | -368 M | - | -326 M | - | -280 M | - | -240 M | - | -208 M | - | -188 M | - | -169 M | - | -152 M | - | -133 M | - | - | - | -89.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | - | 181 M | - | 204 M | - | 180 M | - | 166 M | - | 74.1 M | - | 49.7 M | - | 62.4 M | - | 37.8 M | - | 57.3 M | - | - | - | 74.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | - | 29.5 M | - | 51.8 M | 76 M | 29.3 M | - | 22.3 M | 81.6 M | 29 M | - | 9 M | 23 M | 29 M | - | 5.56 M | 7.56 M | 16.5 M | - | 15.3 M | 29.6 M | 53.8 M | - | - | - | 21.5 M | - | - | - | 5.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
- | - | - | - | 8.88 M | - | 29.6 M | - | 13.9 M | - | 34.6 M | - | 60 M | - | 31.9 M | - | 51.2 M | - | 25.9 M | - | 45.1 M | - | - | - | 62.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | - | 8.88 M | - | 29.6 M | 53 M | 13.9 M | - | 34.6 M | 43.6 M | 60 M | - | 31.9 M | 41.9 M | 51.2 M | - | 25.9 M | 36.3 M | 45.1 M | - | 48.8 M | 58.9 M | 62.7 M | - | - | - | 60.1 M | - | - | - | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency